Bioprocessing development is a long and costly process. Building in continuous characterization and connected bioprocessing cuts timelines and increases the available information through real-time analytics.
Understand the strategies which can be employed at the different stages of development when choosing parenteral dosage forms.
The extensive timeline to develop a drug is due to a multitude of formulation challenges that formulation experts face. When it comes to solving these challenges, there have been significant advancements in drug development techniques to counter these challenges including bioavailability, stability, efficacy, manufacturability, and safety.
Why understanding both the product and every step of the process is crucial in cell and gene therapy production.
To be able to meet the growing needs of patients around the world, a company must have a strategy that can shepherd new biologic therapies throughout the development timeline.
How SYLOID® FP silica products contribute significantly in mitigating/resolving key challenges such as formulation stability over time, ability to withstand challenging processing conditions, and Compatibility with other formulation ingredients.
The combined adsorption capacity, porosity, particle size, and density of the SYLOID® XDP silicas provide a tool to convert liquid ingredients into free flowing powder.
Grace’s SYLOID® 244 FP silica is highly porous and an excellent solution for converting viscous Simethicone into compressible free flowing powder to make chewable tablets.
SYLOID® FP and XDP silicas excipients are micronized synthetic amorphous silica gels of high purity which are widely formulated into many pharmaceutical products.
This moisture activated dry granulation (MADG) technique provides a way to address common problems such as endpoint detection, drying, and milling with an efficient, cost-effective granulating process that utilizes a limited amount of water and does not require a drying step.